Shares of Moderna have moved -6.4% today, and are now trading at a price of $166.08. In contrast, the S&P 500 index saw a 0.5% change and the Dow Industrial Average posted a 0.2% performance. Today's trading volume is 1,801,320 compared to the stock's average volume of 4,706,177.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Based in Cambridge, United States the company has 3,700 full time employees and a market cap of $63,804,616,704.
The company is now trading -20.71% away from its average analyst target price of $209.47 per share. The 15 analysts following the stock have set target prices ranging from $101 to $506, and on average give Moderna a rating of buy.
Over the last year, MRNA shares have gone down by -34.8%, which represents a difference of -19.1% when compared to the S&P 500. The stock's 52 week high is $321.31 per share and its 52 week low is $115.03. Based on Moderna's average gross margin growth of 29.1% over the last four years, its core business remains strong and the stock price may recover in the long term.